<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35334">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149420</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736X2201</org_study_id>
    <secondary_id>2013-000250-22</secondary_id>
    <nct_id>NCT02149420</nct_id>
  </id_info>
  <brief_title>PD of VAY736 in Patients With Primary Sjögren's Syndrome</brief_title>
  <acronym>CVAY736X2201</acronym>
  <official_title>A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sjögren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics and
      therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS
      patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in EULAR Sjögren's syndrome disease activity index (ESSDAI)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The effect of VAY736 on clinical disease activity will be measured by the change in ESSDAI (EULAR Sjögren's syndrome disease activity index) between baseline and week 12. The ESSDAI is a questionnaire containing 12 organ-specific domains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EULAR Sjögren's Syndrome Patient Response Index (ESSPRI)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ESSPRI is a patient self-reported outcome measure (questionnaires) to assess patient's disease status (e.g. pain, emotional/social/physical functioning, mental health, fatigue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form (36) Health Survey (SF-36)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The SF-36 is a patient self-reported outcome measure (questionnaires) to assess patient's disease status and burden, e.g. pain, emotional/social/physical functioning, mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Multidimensional Fatigue Inventory (MFI)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the physician's global assessment by means of Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the patient's global assessment by means of Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The visual analogue scale used is a 100 mm VAS ranging from &quot;no disease&quot; (0 mm) to &quot;maximal disease activity&quot; (100 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAY736 serum concentration</measure>
    <time_frame>0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The concentration of VAY736 will be measured in the serum. Descriptive statistics will include maximum serum concentration, time to reach maximum concentration, area under the concentration curve, half-life, plasma clearance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Sjögren's Syndrome</condition>
  <arm_group>
    <arm_group_label>VAY736 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VAY736 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VAY736</intervention_name>
    <arm_group_label>VAY736 dose 1</arm_group_label>
    <arm_group_label>VAY736 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Fulfilled revised European US consensus criteria for pSS

          -  ESSDAI value ≥ 6

          -  Elevated serum titers at screening of ANA (≥ 1:160)

          -  Seropositive at screening for anti-SSA and/or anti-SSB antibodies

          -  Stimulated whole salivary flow rate at screening of &gt; 0 mL/min

        EXCLUSION CRITERIA:

        - Prior or previous use of (specific dosages and intervals prior to study start may
        apply): B-cell depleting therapy (e.g., rituximab), Prednisone, anti-BAFF mAb, CTLA4-Fc Ig
        (abatacept), anti-TNF-α mAb, cyclophosphamide, azathioprine and medications known to cause
        dry mouth.

        Hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to
        randomization is allowed

          -  Active or recent history of clinically significant infection

          -  Vaccination within 2 month prior to study

          -  History of primary or secondary immunodeficiency

          -  Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <state>the Netherlands</state>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>September 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary Sjögren's syndrome, pharmacodynamics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
